KAALtv.com

Update: OMC, Mayo Joins Others in Faulting FDA Meningitis Report

Posted at: 10/23/2012 10:10 AM
Updated at: 10/23/2012 1:14 PM

(ABC 6 NEWS) -- A report released by the government Monday night has been taken down due to "technical difficulties".

The FDA took down the detailed report, and replaced it with the following message:

NOTE: FDA has found some technical problems with the list and the data are incorrect. FDA is working to correct the list and will re-post when we are sure it is accurate.

On the list released Monday evening, Olmsted Medical Center, along with several Mayo Clinic Health System facilities outside of southeastern Minnesota, were shown to have purchased the drug methylprednisolone acetate from the New England Compounding Center (NECC).  That is the drug that is blamed on numerous illnesses and deaths in 23 states.

Olmsted Medical Center believes that the FDA report was inaccurate, and according to an OMC spokesperson, they believe they did not purchase that particular drug.

A Mayo Clinic spokesperson says the facility in Rochester, nor any of the Mayo Clinic Health System sites have purchased the drugs either.

The FDA is working to correct their findings, and will release an update list.

Several providers in Minnesota and around the country voiced concerns about the FDA report, which lead to the report being removed temporarily.

ABC 6 News is working with OMC and the FDA to determine the risk of the meningitis outbreak locally.

Here is information from the FDA about the meningitis outbreak, and the steps you should take if you feel you might have been exposed to the tainted drug.

 

Patients who believe they received an injection or other product that was shipped by NECC on or after May 21, 2012 should remain vigilant for the signs and symptoms of infection, and contact their health care provider if they are concerned.  The meningitis outbreak has occurred in patients who received injections near the spine (back or neck).  The signs and symptoms of meningitis include fever, headache, stiff neck, nausea and vomiting, photophobia (sensitivity to light) and altered mental status.  Symptoms for infections following other types of injections at other body sites may vary, and are not limited to meningitis.  Other possible infections at other parts of the body (e.g., peripheral joints) may include fever; swelling, increasing pain, redness, warmth at an injection site; visual changes, pain, redness or discharge from the eye; chest pain, or drainage from the surgical site (infection within the chest).  Patients should contact their healthcare provider if they have any of these signs or symptoms. 

Patients who received an NECC product prior to May 21, 2012 and who have not experienced symptoms of infection to date are at less risk of infection because of the amount of time that has elapsed since that date.  FDA is not recommending these patients follow-up with their healthcare providers unless they are experiencing symptoms of infection.